Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IINN 
Inspira Technologies Oxy BHN Ltd (IINN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/21/2025: IINN (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 87% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/21/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 34.82M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta 2.3 | 52 Weeks Range 0.40 - 1.65 | Updated Date 10/21/2025 |
52 Weeks Range 0.40 - 1.65 | Updated Date 10/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.48 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2503.46% |
Management Effectiveness
Return on Assets (TTM) -81.03% | Return on Equity (TTM) -219.74% |
Valuation
Trailing PE - | Forward PE 10.73 | Enterprise Value 34875396 | Price to Sales(TTM) 120.49 |
Enterprise Value 34875396 | Price to Sales(TTM) 120.49 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.15 | Shares Outstanding 30814743 | Shares Floating 27122750 |
Shares Outstanding 30814743 | Shares Floating 27122750 | ||
Percent Insiders 7.83 | Percent Institutions 3.92 |
Upturn AI SWOT
Inspira Technologies Oxy BHN Ltd
Company Overview
History and Background
Inspira Technologies Oxy BHN Ltd. is a medical technology company focusing on acute respiratory care. Founded with the goal of developing innovative respiratory support technology, its journey involves research, development, clinical trials, and regulatory approvals to bring its products to market. Details regarding founding year and key milestones require further research and data retrieval.
Core Business Areas
- Respiratory Support Systems: Development and commercialization of innovative respiratory support devices, particularly the ART system, designed to provide less invasive alternatives to traditional mechanical ventilation.
Leadership and Structure
Information regarding specific leadership team members and detailed organizational structure requires further data retrieval.
Top Products and Market Share
Key Offerings
- ART (Augmented Respiration Technology) System: The ART system is designed to prevent the need for invasive mechanical ventilation. Market share and revenue data are currently unavailable. Competitors in the respiratory support market include Medtronic, Philips, and ResMed.
Market Dynamics
Industry Overview
The respiratory care market is driven by the increasing prevalence of respiratory diseases, aging populations, and technological advancements in respiratory support devices. This market includes ventilation, oxygen therapy, and diagnostic equipment.
Positioning
Inspira Technologies aims to position itself as a provider of less invasive respiratory support solutions, potentially reducing the need for traditional mechanical ventilation and its associated complications. It's positioning is focused on innovation and alternatives.
Total Addressable Market (TAM)
The global respiratory devices market is substantial, estimated to be in the billions of dollars. Inspira Technologies targets a segment of this market with its less invasive ART system. Specific TAM figures and Inspira's positioning relative to it require further research and data retrieval.
Upturn SWOT Analysis
Strengths
- Innovative technology (ART System)
- Potential to reduce reliance on invasive ventilation
- Focus on patient comfort and reduced complications
Weaknesses
- Limited commercialization history
- Dependence on regulatory approvals
- High dependence on key personnel
- Currently operating at a loss.
Opportunities
- Growing demand for less invasive respiratory support
- Expansion into new geographic markets
- Partnerships with hospitals and healthcare providers
- Potential for acquisitions and mergers
Threats
- Competition from established medical device companies
- Regulatory hurdles and delays
- Technological obsolescence
- Economic downturn affecting healthcare spending
- Adverse clinical trial results
Competitors and Market Share
Key Competitors
- MDT
- PHIL
- RMD
Competitive Landscape
Inspira Technologies faces strong competition from established medical device companies. Its competitive advantage lies in its innovative ART system, but it needs to overcome commercialization challenges.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's stage of development.
Future Projections: Future growth projections depend on the successful commercialization of the ART system and require analyst estimates.
Recent Initiatives: Recent initiatives include ongoing clinical trials, regulatory submissions, and strategic partnerships.
Summary
Inspira Technologies is a medical technology company with an innovative ART system for respiratory support. It operates in a competitive market and must overcome commercialization hurdles. The company's success depends on regulatory approvals, partnerships, and market adoption of its technology. It is currently operating at a loss and faces significant competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Public Filings
- Industry Reports (requires further research)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inspira Technologies Oxy BHN Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-07-14 | Co-Founder, CEO & Director Mr. Dagi Shahar Ben-Noon | ||
Sector Healthcare | Industry Medical Devices | Full time employees 38 | Website https://inspira-technologies.com |
Full time employees 38 | Website https://inspira-technologies.com | ||
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacturing, and marketing of proprietary life support technologies for the treatment of acute respiratory failure in Israel. It offers INSPIRA ART100, a life support system used in procedures requiring cardiopulmonary bypass for six hours or less. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'anana, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.